By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

FIND THE BREAST CANCER DRUG INFORMATION YOU NEED
MedSearch

Generic Name

Trastuzumab deruxtecan

Brand Name

Enhertu
AstraZeneca

Product Monograph

Stage IV (metastatic)
HER2+
Targeted therapy
Injectable
Listed on Provincial/Territorial drug Formulary

The process of getting a drug approved and publicly funded in Canada is complex and lengthy. CBCN has created an infographic on how drugs get funded in Canada to make understanding Canada’s drug approval process a little easier. Access the infographic here.

Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Québec, Saskatchewan
No
Yes

To support patients with unresectable or metastatic breast cancer who have been prescribed Enhertu, AstraZeneca has a Patient Support Program (PSP). Patients enrolled in the PSP will have access to educational resources, reimbursement navigation support, and for those with private insurance, co-payment towards the cost of the drug (up to 20 percent). The PSP will also offer a free drug program which will provide financial support for Enhertu at 100% for eligible patients. All new, eligible patients enrolled in the PSP will have access to educational resources, reimbursement navigation, infusion support, and co-payment support toward the cost of Enhertu (up to 20%). If you have questions you can contact the PSP directly at the following:

Phone: 1-877-280-6208
Fax: 1-877-280-6221
Email: enrollment@azoncologypsp.ca